Last reviewed · How we verify
NCT03064399
Microfracture Technique for Talar Articular Cartilage Lesions With or Without Lateral Ligament Repairment
NA trial testing without lateral ligament repairment in Lateral Ligament Repair in 40 participants. Status unknown.
28 May 2019
Quick facts
| Lead sponsor | Shanghai Tongji Hospital, Tongji University School of Medicine |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 28 February 2017 |
| Primary completion | 28 May 2019 |
| Estimated completion | 28 February 2020 |
Drugs / interventions tested
- without lateral ligament repairment
- lateral ligament repairment
Conditions studied
- Lateral Ligament Repair — all drugs for Lateral Ligament Repair →
- Talar Cartilage Lesion — all drugs for Talar Cartilage Lesion →
- Microfracture — all drugs for Microfracture →
Sponsor
Shanghai Tongji Hospital, Tongji University School of Medicine
Who can join
Adults 18 to 40, any sex, with Lateral Ligament Repair or Talar Cartilage Lesion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To study the clinical efficacy of microfracture combined with lateral ligament repairment for cartilage lesions of talus through the comparison between microfracture with and without lateral ligament repairment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03064399
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Shanghai Tongji Hospital, Tongji University School of Medicine trials
Trials by the same sponsor.
- NCT07384390 — TH-CAR-027 for Grade 4 Gliomas · EARLY_PHASE1 · not yet recruiting
- NCT07043218 — A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia · Phase 1 · not yet recruiting
- NCT07064109 — Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS Patients · NA · recruiting
- NCT06951425 — An Exploratory Clinical Study of the Efficiency and Safety of TH027 in the Treatment of Relapsed/Refractory Solid Tumors · EARLY_PHASE1 · not yet recruiting
- NCT06987916 — Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03064399 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Tongji Hospital, Tongji University School of Medicine
- Last refreshed: 27 February 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03064399.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing